Filter by: patients
What is Megestrol?

Megestrol is a progestin, an apetitie stimulant and an antineoplastic agent. It is used for palliative treatment of breast and endometrial carcinoma; treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Decreased appetite 5 0
Pre cancer cells in uterus 1 1 Efficacy_cant_tell
Loss of appetite 1 1 Efficacy_major
appittite 1 1 Efficacy_major
Uterine cancer 1 0

See all 6 patients currently taking Megestrol

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
3

Reported Dosages

  40mg/mL as needed 1 mg daily 2 tps. daily 40 mg daily 625 mg/5 mL daily
  2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Megestrol (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 2   Course of treatment ended: 50%
Did not seem to work 1   Did not seem to work: 25%
Other 1   Other: 25%

See all 4 patients who’ve stopped taking Megestrol

Currently Taking Megestrol

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Megestrol

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Megestrol

Always
2 67%
Usually
1 33%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Megestrol

Very
0 0%
Somewhat
0 0%
A little
1 33%
Not at all
2 67%

Cost

Paid out of pocket

Cost of Megestrol

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
2 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 27, 2012.